Advanced Accelerator Applications
在场
Advanced Accelerator Applications 的所有者是 Novartis.
是其中之一......
- Forbes Global 2000 (#94);
- Fortune 500 Europe (#58);
- Global Fortune 500 (#271);
- Stoxx 600;
- Swiss market index.
Novartis 是一家在股票代码 NOVN (CH) 下上市的公司。
Novartis 在 37 个国家有直接业务。Novartis 拥有 69家子公司，其中包括 Advanced Accelerator Applications、Alcon 和 Alcon ANZ。
他们在：
涉及Novartis的并购和融资。
- Novartis has announced the acquisition of Chinook Therapeutics (公布2023八月14号).
- Novartis has announced the acquisition of DTx Pharma (公布2023七月18号).
- Novartis has announced the acquisition of Chinook Therapeutics (公布2023六月15号).
高管
查看带有其 13 名主要高管的组织结构图
Advanced Accelerator Applications 搜索最多的简介
- Sidonie Golombowski-Daffner, Country President and Pharma General ...
- Jessica Toepfer, Non-Executive Director
- Frederic Collet, Non-Executive Director
高管在Novartis变化
- Patrick HorberPatrick Horber 将于202311月1作为 President, International 加入公司 (新闻发布的2023九月7号).
- Marie-France Tschudin, President, Innovative Medicines International & Chief Commercial Officer, 将于 20239月15 退休 (新闻发布的2023九月6号).
创建提醒
跟踪 Advanced Accelerator Applications 的高管变动
药店
Novartis 拥有 1,868 家竞争者，其中包括 Pfizer (美国(美洲))、Sanofi (法国) 和 Johnson & Johnson (美国(美洲))。
Popular M&A news in 药店
- AstraZeneca has announced the acquisition of Fusion Pharma (公布2024三月23号).
- AstraZeneca has announced the acquisition of Amolyt Pharma (公布2024三月19号).
- Frontier Medicines 刚刚宣布为 80 筹款数百万美元。 (公布2024二月27号).
药店 行业的其他推荐联系人
消息
Advanced Accelerator Applications 的最新新闻稿
- Novartis implements manufacturing adjustments for ribociclib to ensure alignment with latest regulatory standards in eBC by end of Q2
- Novartis tender offer for MorphoSys AG commences
- New Novartis data show early addition of twice-yearly* Leqvio® (inclisiran) following maximally tolerated statin therapy significantly reduces LDL-C in ASCVD patients in real-world setting
- Novartis confirms plans to file for Pluvicto® pre-taxane label expansion in H2 2024 based on latest data from Phase III PSMAfore study
- Novartis Fabhalta® (iptacopan) receives positive CHMP opinion as first oral monotherapy for adult patients with paroxysmal nocturnal hemoglobinuria (PNH)
- Aktionärinnen und Aktionäre von Novartis heissen an der ordentlichen Generalversammlung alle Anträge des Verwaltungsrats gut
- Les actionnaires de Novartis approuvent toutes les résolutions proposées par le Conseil d’administration lors de l’Assemblée générale ordinaire
- Novartis shareholders approve all resolutions proposed by the Board of Directors at the Annual General Meeting
- News Archive | Novartis
- Novartis presents new data on safety and efficacy of Zolgensma, including maintained and improved motor milestones in older and heavier children with SMA
- View more press releases Close
通过电子邮件
